Despite increasing evidence to support the relationship between FUBP1 and
tumorigenesis in some types of
cancers, there have been no analyses from a pan-
cancer perspective. Here, we are the first to investigate the putative oncogenic role of FUBP1 in 33
cancer types based on The
Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. Dysregulated FUBP1 expression was observed in most
cancer types, and high FUBP1 expression suggests poor prognosis in
cancers such as ACC, KICH, LIHC, LUAD, LUSC, SARC, CESC, and SKCM. Missense mutation is the most common type of FUBP1 mutation, and R430 in KH_4 is a predominant mutation site. Enhanced phosphorylation of FUBP1 at the S120 site has been observed in clear cell RCC,
lung adenocarcinoma, and pediatric
brain cancer specimens from African-American and Asian individuals. The expression of FUBP1 was found to be negatively correlated with the infiltration of CD8+ T lymphocytes in GBM, HNSC-HPV- and UCEC but positively correlated with that of tumor-associated fibroblasts in CESC, ESCA, HNSC, LIHC, LUAD, PAAD, and THYM. Furthermore, RNA splicing and spliceosome signaling were predominantly enriched in both GO and KEGG analyses of the functional mechanism of FUBP1. Briefly, this pan-
cancer analysis comprehensively revealed the multifaceted characteristics and oncogenic role of FUBP1 in different human
cancers.